Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2025)

Candel Therapeutics has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $2.3 million for Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at $2.3 million, up 320.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.3 million (up 197.75% YoY), and the FY2025 annual result was $2.3 million, up 197.75% from the prior year.
• Change in Accured Expenses came in at $2.3 million for Q4 2025 at Candel Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2025 to a low of -$2.4 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $493500.0 (2024), against an average of $213600.0.
• Across the five-year window, Change in Accured Expenses slumped 2088.89% in 2023 and jumped 1692.94% in 2024, its largest moves.
• Candel Therapeutics' Change in Accured Expenses stood at $719000.0 in 2021, then slumped by 39.5% to $435000.0 in 2022, then surged by 117.47% to $946000.0 in 2023, then sank by 42.49% to $544000.0 in 2024, then soared by 320.77% to $2.3 million in 2025.
• The last three Change in Accured Expenses figures came in at $2.3 million (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.